Results 71 to 80 of about 2,075,344 (349)

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

JAMA Oncology, 2020
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone
K. Shitara, E. Van Cutsem, Y. Bang, C. Fuchs, L. Wyrwicz, Keun-Wook Lee, I. Kudaba, M. Garrido, H. Chung, Jeeyun Lee, H. Castro, Wasat Mansoor, M. Braghiroli, N. Karaseva, C. Caglevic, L. Villanueva, E. Goekkurt, H. Satake, P. Enzinger, M. Alsina, A. Benson, J. Chao, A. Ko, Z. Wainberg, U. Kher, Sukrut Shah, S. Kang, J. Tabernero   +27 more
semanticscholar   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

Aerosolized Chemotherapy [PDF]

Journal of Aerosol Medicine, 2008
Regional chemotherapy has been proposed as a treatment modality in a number of cancer settings. In primary or metastatic lung cancer, administration of chemotherapy via inhalation could increase exposure of lung tumor to the drug, while minimizing systemic side effects.
Gagnadoux, Frédéric, Hureaux, José, Vecellio, Laurent, Urban, Thierry, Le Pape, Alain, Valo, Isabelle, Montharu, Jerome, Leblond, Valérie, Boisdron-Celle, Michele, Lerondel, Stephanie, Majoral, Caroline, Diot, Patrice, Racineux, Jean-Louis, Lemarié, Etienne   +13 more
openaire   +2 more sources

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

New England Journal of Medicine, 2019
BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with
A. Perl, G. Martinelli, J. Cortes, A. Neubauer, E. Berman, S. Paolini, P. Montesinos, M. Baer, R. Larson, C. Ustun, F. Fabbiano, H. Erba, A. Di Stasi, R. Stuart, R. Olin, M. Kasner, F. Ciceri, W. Chou, N. Podoltsev, C. Récher, Hisayuki Yokoyama, N. Hosono, S. Yoon, Je-Hwan Lee, T. Pardee, A. Fathi, Chaofeng Liu, N. Hasabou, Xuan Liu, E. Bahceci, M. Levis   +30 more
semanticscholar   +1 more source

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Journal of Clinical Oncology, 2020
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced ...
T. Kojima, M. Shah, K. Muro, E. François, A. Adenis, Chih-Hung Hsu, T. Doi, T. Moriwaki, Sung-Bae Kim, Se-Hoon Lee, J. Bennouna, Ken Kato, L. Shen, P. Enzinger, S. Qin, P. Ferreira, Jia Chen, G. Girotto, C. de la Fouchardière, H. Sénellart, R. Al-Rajabi, F. Lordick, Rui-xue Wang, S. Suryawanshi, P. Bhagia, S. Kang, J. Metges   +26 more
semanticscholar   +1 more source

Developmental Disorders in Children Recently Diagnosed With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurocognitive deficits in adult survivors of childhood cancer are well established, but less is known about developmental disorders (DD) arising shortly after cancer diagnosis. Using 2016–2019 linked Ohio cancer registry and Medicaid data, we compared DD among 324 children with cancer and 606,913 cancer‐free controls.
Jamie Shoag, Long Vu, Ritika Miryala, Jeffrey M. Albert, Molly McVoy, Siran M. Koroukian   +5 more
wiley   +1 more source

Characterizing Parental Concerns About Lasting Impacts of Treatment in Children With B‐Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐acute lymphoblastic leukemia (B‐ALL) is the most common pediatric cancer, and while most children in high‐resource settings are cured, therapy carries risks for long‐term toxicities. Understanding parents’ concerns about these late effects is essential to guide anticipatory support and inform evolving therapeutic approaches ...
Kellee N. Parker, Sarah W. Alexander, Lisa M. Jacola, Kimberly A. Buff, Kyobin Hwang, Elham Hashemi, Gregory Stoddard, Lindsay A. Jibb   +7 more
wiley   +1 more source

Repurposing Metformin: Potential as a Prevention, Treatment and Adjunct Therapy in Pancreatic Cancer

Quality in Sport
Metformin, a widely prescribed treatment for type II diabetes, offers promising benefits beyond glycemic control, including improved lipid profiles and cardiovascular outcomes.
Emilia Kamizela, Anna Rudzińska, Kacper Ponikowski, Kacper Wrzosek, Paulina Gumółka, Jakub Oberda, Alicja Paluch, Sylwia Haba, Karol Jakubik, Eliza Kolasa, Katarzyna Szklener   +10 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Real‐time assay of ribonucleotide reductase activity with a fluorescent RNA aptamer

FEBS Letters, EarlyView.
Ribonucleotide reductases (RNR) synthesize DNA building blocks de novo, making them crucial in DNA replication and drug targeting. FLARE introduces the first single‐tube real‐time coupled RNR assay, which enables isothermal tracking of RNR activity at nanomolar enzyme levels and allows the reconstruction of allosteric regulatory patterns and rapid ...
Jacopo De Capitani, Noemi E. Nwosu, Viktoria Gocke, Müge Kasanmascheff, Hannes Mutschler   +4 more
wiley   +1 more source